Deep brain stimulation (DBS) has been effective in the treatment of movement disorders such as Parkinson’s disease, tremor, dystonia, and increasingly in the investigational treatment of psychiatric disorders such as obsessive-compulsive disorder and tic disorders. However, conventional DBS is a 4-contact, cylindrical electrode with a large contact area, which can easily lead to stimulation of other areas and cause side effects such as muscle contraction, dysarthria, and cognitive or behavioral impairment. Recently, M. Fiorella Contarino, PhD, Neurology, Academic Medical Center, University of Amsterdam, The Netherlands, et al. presented in the September 2014 issue of Neurology their new development of a deep brain stimulation electrode with 32 contacts that allows manipulation of stimulation direction and recording of local potentials. The authors conducted a single-center, double-blind study to evaluate the safety and efficacy of these manipulable electrodes in DBS procedures in the basal thalamic nucleus of patients with Parkinson’s disease and to explore the possibility of intraoperatively modulating the gain threshold and the side effect threshold of the new electrodes. The results showed that there were no adverse events associated with the test device during the application of the new electrodes. For 13 of the 15 patients (87%) who experienced side effects, the intraoperative stimulation threshold could be increased by ≥1 mA in at least one direction compared to conventional spherical stimulation electrodes, which was tolerated by the patient, thus improving the treatment time window by 1.5 mA. Spatio-temporal information on pathological neural activity generated by local potentials could also be recorded by the 32 contact electrodes. This study shows that the new controllable intracerebral current device can improve the efficacy of deep brain stimulation; its application value is confirmed. And it creates conditions for in-depth research on neuropathic physiological activity. The evidence level of the above study is IV. Patients with Parkinson’s disease tolerate directionally controlled DBS currents well, resulting in an increased threshold for side effects. The new electrode helps to improve the treatment time window of DBS in the basal thalamic nucleus compared to the current spherical stimulation electrode.